Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Edan

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
Multiple Sclerosis and Related Disorders|January 22, 2019
First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre studyNoëlle Lavandier, Mickaël Bonnan, Clarisse Carra-Dallière, et al.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 24, 2018
Measurement of magnetization transfer ratio (MTR) from cervical spinal cord: Multicenter reproducibility and variabilityBenoit Combès, Laureline Monteau, Elise Bannier, et al.
Neurology|October 11, 2015
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITKassandra L Munger, Kathryn C Fitzgerald, Mark S Freedman, et al.
Scientific Reports|May 21, 2026
Performances of experts and automated methods on new multiple sclerosis lesions detection: insights from the MSSeg2 challengeArthur Masson, Benoit Combès, Anne Kerbrat, et al.
Journal of Neurology|April 5, 2025
Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-upJérémy Hong, Malo Gaubert, Mathilde Lefort, et al.
Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.
The New England Journal of Medicine|January 26, 2007
Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle, Christoph Pohl, Matthias Mehling, et al.
Frontiers in Neurology|June 19, 2026
Global overview of multiple sclerosis care units: an international cross-sectional surveyPer Soelberg Sörensen, Paola F Zaratin, Mario Alberto Battaglia, et al.
Multiple Sclerosis and Related Disorders|October 22, 2023
Impact of automatic tools for detecting new lesions on therapeutic strategies offered to patients with MS by neurologistsBlandine Merkler, Arthur Masson, Jean Christophe Ferré, et al.
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
Multiple Sclerosis and Related Disorders|January 22, 2019
First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre studyNoëlle Lavandier, Mickaël Bonnan, Clarisse Carra-Dallière, et al.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 24, 2018
Measurement of magnetization transfer ratio (MTR) from cervical spinal cord: Multicenter reproducibility and variabilityBenoit Combès, Laureline Monteau, Elise Bannier, et al.
Neurology|October 11, 2015
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITKassandra L Munger, Kathryn C Fitzgerald, Mark S Freedman, et al.
Scientific Reports|May 21, 2026
Performances of experts and automated methods on new multiple sclerosis lesions detection: insights from the MSSeg2 challengeArthur Masson, Benoit Combès, Anne Kerbrat, et al.
Journal of Neurology|April 5, 2025
Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-upJérémy Hong, Malo Gaubert, Mathilde Lefort, et al.
Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.
The New England Journal of Medicine|January 26, 2007
Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle, Christoph Pohl, Matthias Mehling, et al.
Frontiers in Neurology|June 19, 2026
Global overview of multiple sclerosis care units: an international cross-sectional surveyPer Soelberg Sörensen, Paola F Zaratin, Mario Alberto Battaglia, et al.
Multiple Sclerosis and Related Disorders|October 22, 2023
Impact of automatic tools for detecting new lesions on therapeutic strategies offered to patients with MS by neurologistsBlandine Merkler, Arthur Masson, Jean Christophe Ferré, et al.
Pageof 15